Form 483

Sombra Cosmetics, Inc Form 483, 2024-07-26

FDA issued a Form 483 to Sombra Cosmetics, Inc on 2024-07-26 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Sombra Cosmetics, Inc · Albuquerque, United States · Issued July 26, 2024

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

26 Jul 2024
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Carolina D Vasquez

26 Jul 2024
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Carolina D Vasquez

26 Jul 2024
21 CFR 211.165(e)

Test methods

Cited by Carolina D Vasquez

26 Jul 2024
21 CFR 211.166(a)

Lack of written stability program

Cited by Carolina D Vasquez

26 Jul 2024
21 CFR 211.180(e)

Records reviewed annually

Cited by Carolina D Vasquez

Inspected site

SCSombra Cosmetics, IncAlbuquerque, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.180(e)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere